Ladarixin

Drug Profile

Ladarixin

Alternative Names: DF-2156A; DF-2156Y; Meraxin

Latest Information Update: 15 Dec 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dompe Farmaceutici
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus
  • Discontinued Bullous pemphigoid; Malignant melanoma; Spinal cord injuries

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 15 Dec 2015 Phase-II clinical trials in Type-1 diabetes mellitus (Newly diagnosed) in Italy (PO) (Dompé Farmaceutici Pipeline, December 2015; NCT02814838)
  • 26 Aug 2015 Phase-I development for new-onset Type-1 diabetes mellitus is ongoing in Italy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top